Impavid srl

Who we are 

Impavid srl is an innovative startup founded with the aim of developing the first bioartificial,  biomimetic, electroconductive and biodegradable cardiac patch to improve the quality of life of  patients affected by myocardial infarction. This device represents an important advance in the  treatment of post-infarction pathologies and aims to prevent the onset of post-ischemic heart failure.  The technology behind the patch is the result of intensive research and development carried out by a multidisciplinary team, divided between Turin and Pisa, and composed of experts in biomaterials,  biomedical engineering and translational medicine. Impavid stands out for its integrated approach,  which ranges from prototyping to pre-clinical studies, with the aim of reaching the international market  soon, overcoming the limits of existing solutions. 

What we do 

Our main product is an innovative heart patch which, thanks to its bio-artificial and biomimetic  composition, is able to adapt perfectly to the morphology of cardiac tissue, ensuring perfect  mechanical compliance and promoting cell alignment and differentiation. A distinctive element is  its ability to biodegrade over time without leaving traces, supporting a process of repair and preservation  of heart tissue. Our solution offers significant competitive advantages over traditional patches due to  its biocompatibility, versatility and scalability for industrial applications. Currently, Impavid srl is  working with strategic partners to advance the preclinical studies and bring the device to market, with  the aim of obtaining approval from major regulatory agencies such as FDA and CE. 

Collaborations with Universities

The IMPAVID team is actively collaborating with prestigious academic institutions to advance  research and development of their own technologies. Claudia Giachino and Raffaella Rastaldo,  respectively Ordinary Professor and Associate Professor at the University of Turin (UNITO), make a  fundamental contribution, as co-founders, through their expertise in translational medicine and tissue  regeneration. Roberto Vanni, PhD student at UNITO, combines scientific expertise with training in  strategy and fundraising, acquiring new skills in management and finance. Niccoletta Barbani, in  collaboration with the University of Pisa (UNIPI), and Caterina Cristallini, First Researcher at the CNR  (National Research Council), are engaged in the research and development of innovative biomaterials.  These academic collaborations are essential for the validation of Impavid’s bioartificial solutions and  the advancement of high-level preclinical and clinical studies.